Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03GYK
|
|||
| Former ID |
DPR000067
|
|||
| Drug Name |
Laropiprant+niacin
|
|||
| Synonyms |
Tredaptive (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dyslipidemia [ICD-11: 5C80-5C81; ICD-9: 272] | Discontinued in Phase 3 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H24ClFN2O6S
|
|||
| Canonical SMILES |
CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F.C1=CC(=CN=C1)C(=O)O
|
|||
| InChI |
1S/C21H19ClFNO4S.C6H5NO2/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12;8-6(9)5-2-1-3-7-4-5/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26);1-4H,(H,8,9)/t13-;/m1./s1
|
|||
| InChIKey |
ZZRFQBQNZLFESZ-BTQNPOSSSA-N
|
|||
| CAS Number |
CAS 1046050-73-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| SuperDrug ATC ID |
C04AC01
|
|||
| SuperDrug CAS ID |
cas=000059676
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor (PTGDR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pathwhiz Pathway | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | |||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01054508) Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers. U.S. National Institutes of Health. | |||
| REF 2 | Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.